Group 1 - The core viewpoint of the article is that the investment by Huayi Family in Haihe Pharmaceutical is a strategic response to the pressures of transformation faced by traditional industries, supported by policy and market logic [1][4] - The "Six Merger Guidelines" issued by the CSRC in 2024 encourage listed companies to engage in cross-industry mergers to enhance industrial transformation and upgrade, providing institutional support for traditional enterprises [1][2] - Traditional industries, including real estate, are experiencing common issues of sluggish growth, with many companies facing performance declines, highlighting the urgent need for transformation [1][3] Group 2 - Compared to building teams to enter new fields, investing in or acquiring mature innovative companies is a more efficient choice, aligning with the "Six Merger Guidelines" that direct resources towards new productive forces [2] - Haihe Pharmaceutical possesses clear core value through its solid R&D capabilities and commercial progress, having undertaken significant national projects and achieved commercialization of several products [3] - Despite currently being in a loss-making state, Haihe Pharmaceutical's situation aligns with the characteristics of innovative pharmaceutical companies, which typically require substantial upfront R&D investments [3] Group 3 - The investment strategy reflects practicality, utilizing a "strategic financial investment" approach to minimize integration risks and allow for future collaboration [4] - The transaction complies with regulatory requirements, ensuring protection for minority investors by involving shareholder meetings and avoiding conflicts of interest [4] - Huayi Family's financial strength supports the feasibility of the operation, with sufficient cash reserves to accommodate the investment without jeopardizing ongoing operations [4]